Recent developments and highlights in drug hypersensitivity.
allergy diagnosis
allergy treatment
basic mechanisms
drug allergy
epidemiology
Journal
Allergy
ISSN: 1398-9995
Titre abrégé: Allergy
Pays: Denmark
ID NLM: 7804028
Informations de publication
Date de publication:
12 2019
12 2019
Historique:
received:
14
06
2019
revised:
18
09
2019
accepted:
19
09
2019
pubmed:
27
9
2019
medline:
10
9
2020
entrez:
27
9
2019
Statut:
ppublish
Résumé
Drug hypersensitivity reactions (DHRs) are nowadays the third cause of allergy after rhinitis and asthma with a significant increase in prevalence in both adults and paediatric population with new drugs included as culprit. For this, DHRs represent not only a health problem but also a significant financial burden for affected individuals and health systems. Mislabelling DHRs is showing to be a relevant problem for both, false label of drug allergic and false label of nonallergic. All this reinforces the need to improve accurate diagnostic approaches that allow an appropriate management. Moreover, there is a need for training both, nonallergist stakeholders and patients to improve the reaction identification and therefore decrease the mislabelling. The use of allergy cards has shown to be relevant to avoid the induction of DHRs due to the prescription of wrong medication. Recent developments over the last 2 years and highlights about risk factors, diagnostic approaches, mechanisms involved as well as prevention actions, and management have been reviewed. In these papers, it has been outlined the need for correct diagnosis and de-labelling of patients previously false-reported as allergic, which will improve the management and treatment of patients with DHRs.
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
2368-2381Subventions
Organisme : Consejería de Salud, Junta de Andalucía
ID : C-0004-2016C
Pays : International
Organisme : Consejería de Salud, Junta de Andalucía
ID : PI-0241-2016; PE-0172-2018
Pays : International
Organisme : Instituto de Salud Carlos III
ID : PI15/01206
Pays : International
Organisme : Instituto de Salud Carlos III
ID : PI18/00095
Pays : International
Organisme : Instituto de Salud Carlos III
ID : RD16/0006/0001
Pays : International
Organisme : Instituto de Salud Carlos III
ID : RD16/0006/0019; CP15/00103; PI17/01237
Pays : International
Organisme : Secretaría de Estado de Investigación, Desarrollo e Innovación
ID : RYC-2013-13138
Pays : International
Informations de copyright
© 2019 EAACI and John Wiley and Sons A/S. Published by John Wiley and Sons Ltd.
Références
Thong BY, Tan TC. Epidemiology and risk factors for drug allergy. Br J Clin Pharmacol. 2011;71(5):684-700.
Ojeda P, Sastre J, Olaguibel JM, Chivato T, investigators participating in the National Survey of the Spanish Society of A, Clinical Immunology A. Alergologica 2015: a national survey on allergic diseases in the adult Spanish population. J Investig Allergol Clin Immunol. 2018;28(3):151-164.
Wong A, Seger DL, Lai KH, Goss FR, Blumenthal KG, Zhou L. Drug hypersensitivity reactions documented in electronic health records within a large Health System. J Allergy Clin Immunol Pract. 2019;7(4):1253-1260 e3.
Demoly P, Adkinson NF, Brockow K, et al. International Consensus on drug allergy. Allergy. 2014;69(4):420-437.
Brockow K, Ardern-Jones MR, Mockenhaupt M, et al. EAACI position paper on how to classify cutaneous manifestations of drug hypersensitivity. Allergy. 2019;74(1):14-27.
Dhopeshwarkar N, Sheikh A, Doan R, et al. Drug-induced anaphylaxis documented in electronic health records. J Allergy Clin Immunol Pract. 2019;7(1):103-111.
Mota I, Gaspar A, Benito-Garcia F, Correia M, Chambel M, Morais-Almeida M. Drug-induced anaphylaxis: seven-year single-center survey. Eur Ann Allergy Clin Immunol. 2018;50(5):211-216.
Meng J, Rotiroti G, Burdett E, Lukawska JJ. Anaphylaxis during general anaesthesia: experience from a drug allergy centre in the UK. Acta Anaesthesiol Scand. 2017;61(3):281-289.
Al-Ahmad M, Rodriguez BT. Pattern of inpatient referrals to a drug allergy unit in Kuwait. Eur Ann Allergy Clin Immunol. 2017;49(6):276-280.
Deng Q, Fang X, Zeng Q, Lu J, Jing C, Huang J. Severe cutaneous adverse drug reactions of Chinese inpatients: a meta-analysis. An Bras Dermatol. 2017;92(3):345-349.
Cavkaytar O, Karaatmaca B, Cetinkaya PG, et al. Characteristics of drug-induced anaphylaxis in children and adolescents. Allergy Asthma Proc. 2017;38(5):56-63.
Gabrielli S, Clarke AE, Eisman H, et al. Disparities in rate, triggers, and management in pediatric and adult cases of suspected drug-induced anaphylaxis in Canada. Immun Inflamm Dis. 2018;6(1):3-12.
Kuyucu S, Caubet JC. Hypersensitivity reactions to antiepileptic drugs in children: epidemiologic, pathogenetic, clinical, and diagnostic aspects. J Allergy Clin Immunol Pract. 2018;6(6):1879-1891.e1.
Syu FK, Pan HY, Chuang PC, Huang YS, Cheng CY, Cheng FJ. Incidence of Stevens-Johnson syndrome following combination drug use of allopurinol, carbamazepine and phenytoin in Taiwan: a case-control study. J Dermatol. 2018;45(9):1080-1087.
Santos RB, Galvao VR. Monoclonal antibodies hypersensitivity: prevalence and management. Immunol Allergy Clin North Am. 2017;37(4):695-711.
Ford M, Sahbudin I, Filer A, Steven N, Fisher BA. High proportion of drug hypersensitivity reactions to sulfasalazine following its use in anti-PD-1-associated inflammatory arthritis. Rheumatology (Oxford). 2018;57(12):2244-2246.
Yang MS, Kim JY, Kang MG, et al. Direct costs of severe cutaneous adverse reactions in a tertiary hospital in Korea. Korean J Intern Med. 2019;34(1):195-201.
Casciaro M, Navarra M, Inferrera G, Liotta M, Gangemi S, Minciullo PL. PPI adverse drugs reactions: a retrospective study. Clin Mol Allergy. 2019;17:1.
Lin CY, Wang CW, Hui CR, et al. Delayed-type hypersensitivity reactions induced by proton pump inhibitors: A clinical and in vitro T-cell reactivity study. Allergy. 2018;73(1):221-229.
Jaoui A, Delalande D, Siouti S, et al. Safety and cost effectiveness of supervised ambulatory drug provocation tests in children with mild non-immediate reactions to beta-lactams. Allergy. 2019. [Epub ahead of print]
Mattingly TJ 2nd, Fulton A, Lumish RA, et al. The cost of self-reported penicillin allergy: a systematic review. J Allergy Clin Immunol Pract. 2018;6(5):1649-1654 e4.
Turner PJ, Jerschow E, Umasunthar T, Lin R, Campbell DE, Boyle RJ. Fatal anaphylaxis: mortality rate and risk factors. J Allergy Clin Immunol Pract. 2017;5(5):1169-1178.
Tai YH, Tai YJ, Hsu HC, et al. Risk factors of hypersensitivity to carboplatin in patients with gynecologic malignancies. Front Pharmacol. 2017;8:800.
Sohn KH, Kang DY, Kim JY, et al. Incidence and risk of oxaliplatin-induced hypersensitivity in patients with asymptomatic prior exposure. A prospective observational study. J Allergy Clin Immunol Pract. 2018;6(5):1642-1648 e2.
Bielen C, Bielen L, Likic R. Incidence, etiology, predictors and outcomes of suspected drug hypersensitivity reactions in a tertiary care university hospital's emergency department : A retrospective study. Wien Klin Wochenschr. 2019;131(13-14):329-336.
Guvenir H, Dibek Misirlioglu E, Capanoglu M, et al. The frequency of nonsteroidal anti-inflammatory drug hypersensitivity in children with asthma. Int Arch Allergy Immunol. 2018;176(1):26-32.
Kowalski ML, Agache I, Bavbek S, et al. Diagnosis and management of NSAID-exacerbated respiratory disease (N-ERD)-a EAACI position paper. Allergy. 2019;74(1):28-39.
Park HJ, Park JW, Yang MS, et al. Re-exposure to low osmolar iodinated contrast media in patients with prior moderate-to-severe hypersensitivity reactions: a multicentre retrospective cohort study. Eur Radiol. 2017;27(7):2886-2893.
Eaddy Norton A, Broyles AD. Drug allergy in children and adults: is it the double X chromosome? Ann Allergy Asthma Immunol. 2019;122(2):148-155.
Kim SY, Kim MH, Cho YJ. Different clinical features of anaphylaxis according to cause and risk factors for severe reactions. Allergol Int. 2018;67(1):96-102.
Ventura MT, Boni E, Cecere R, et al. Importance of hypersensitivity in adverse reactions to drugs in the elderly. Clin Mol Allergy. 2018;16:7.
McDerby N, Kosari S, Bail K, Shield A, Peterson G, Naunton M. The effect of a residential care pharmacist on medication administration practices in aged care: a controlled trial. J Clin Pharm Ther. 2019;44(4):595-602.
Negrini S, Becquemont L. HLA-associated drug hypersensitivity and the prediction of adverse drug reactions. Pharmacogenomics. 2017;18(15):1441-1457.
Fernandez TD, Mayorga C, Guéant JL, Blanca M, Cornejo-García JA. Contributions of pharmacogenetics and transcriptomics to the understanding of the hypersensitivity drug reactions. Allergy. 2014;69(2):150-158.
Zhao Q, Alhilali K, Alzahrani A, et al. Dapsone- and nitroso dapsone-specific activation of T cells from hypersensitive patients expressing the risk allele HLA-B*13:01. Allergy. 2019;74(8):1533-1548.
Yampayon K, Sukasem C, Limwongse C, et al. Influence of genetic and non-genetic factors on phenytoin-induced severe cutaneous adverse drug reactions. Eur J Clin Pharmacol. 2017;73(7):855-865.
Shi YW, Min FL, Zhou D, et al. HLA-A*24:02 as a common risk factor for antiepileptic drug-induced cutaneous adverse reactions. Neurology. 2017;88(23):2183-2191.
Konvinse KC, Trubiano JA, Pavlos R, et al. HLA-A*32:01 is strongly associated with vancomycin-induced drug reaction with eosinophilia and systemic symptoms. J Allergy Clin Immunol. 2019;144(1):183-192.
Prasertvit P, Chareonyingwattana A, Wattanakrai P. Nevirapine patch testing in Thai human immunodeficiency virus infected patients with nevirapine drug hypersensitivity. Contact Dermatitis. 2017;77(6):379-384.
Singvijarn P, Manuyakorn W, Mahasirimongkol S, et al. Association of HLA genotypes with Beta-lactam antibiotic hypersensitivity in children. Asian Pac J Allergy Immunol. 2019. [Epub ahead of print]
Nakkam N, Konyoung P, Kanjanawart S, et al. HLA pharmacogenetic markers of drug hypersensitivity in a Thai population. Front Genet. 2018;9:277.
Chen JR, Tarver SA, Alvarez KS, Tran T, Khan DA. A proactive approach to penicillin allergy testing in hospitalized patients. J Allergy Clin Immunol Pract. 2017;5(3):686-693.
Rebelo Gomes E, Geraldes L, Gaspar A, et al. Hypersensitivity reactions to nonsteroidal anti-inflammatory drugs among adults: clinical features and risk factors for diagnosis confirmation. Int Arch Allergy Immunol. 2016;171(3-4):269-275.
Kvisselgaard AD, Mosbech HF, Fransson S, Garvey LH. Risk of immediate-type allergy to local anesthetics is overestimated-results from 5 years of provocation testing in a danish allergy clinic. J Allergy Clin Immunol Pract. 2018;6(4):1217-1223.
Su T, Broekhuizen B, Verheij T, Rockmann H. The impact of penicillin allergy labels on antibiotic and health care use in primary care: a retrospective cohort study. Clin Transl Allergy. 2017;7:18.
Inglis JM, Caughey GE, Smith W, Shakib S. Documentation of penicillin adverse drug reactions in electronic health records: inconsistent use of allergy and intolerance labels. Intern Med J. 2017;47(11):1292-1297.
Dibek Misirlioglu E, Guvenir H, Ozkaya Parlakay A, et al. Incidence of antibiotic-related rash in children with epstein-barr virus infection and evaluation of the frequency of confirmed antibiotic hypersensitivity. Int Arch Allergy Immunol. 2018;176(1):33-38.
Abrams EM, Atkinson AR, Wong T, Ben-Shoshan M. The importance of delabeling beta-lactam allergy in children. J Pediatr. 2019;204:291-297.e1.
Dona I, Barrionuevo E, Salas M, et al. Natural evolution in patients with nonsteroidal anti-inflammatory drug-induced urticaria/angioedema. Allergy. 2017;72(9):1346-1355.
Miller J, Clough SB, Pollard RC, Misbah SA. Outcome of repeat anaesthesia after investigation for perioperative anaphylaxis. Br J Anaesth. 2018;120(6):1195-1201.
Sousa-Pinto B, Fonseca JA, Gomes ER. Frequency of self-reported drug allergy: a systematic review and meta-analysis with meta-regression. Ann Allergy Asthma Immunol. 2017;119(4): 362-373.e2.
Lucas M, Loh RK, Smith WB. Improving drug allergy management in Australia: education, communication and accurate information. Med J Aust. 2018;210(2):62-64.
Sommerfield DL, Sommerfield A, Schilling A, Slevin L, Lucas M, von Ungern-Sternberg BS. Allergy alerts - The incidence of parentally reported allergies in children presenting for general anesthesia. Paediatr Anaesth. 2019;29(2):153-160.
Moreno E, Laffond E, Munoz-Bellido F, et al. Performance in real life of the European network on drug allergy algorithm in immediate reactions to beta-lactam antibiotics. Allergy. 2016;71(12):1787-1790.
Dona I, Barrionuevo E, Salas M, et al. NSAIDs-hypersensitivity often induces a blended reaction pattern involving multiple organs. Sci Rep. 2018;8(1):16710.
Yang MS, Choi SI, Song WJ, et al. Electronic consultation support system for radiocontrast media hypersensitivity changes clinicians' behavior. Allergy Asthma Immunol Res. 2018;10(2):165-171.
Phan A, Allen B, Epps K, Alikhil M, Kamataris K, Tucker C. Initiative to reduce aztreonam use in patients with self-reported penicillin allergy: Effects on clinical outcomes and antibiotic prescribing patterns. Am J Health Syst Pharm. 2018;75(17_Supplement_3):S58-S62.
Muraro A, Fernandez-Rivas M, Beyer K, et al. The urgent need for a harmonized severity scoring system for acute allergic reactions. Allergy. 2018;73(9):1792-1800.
Slight SP, Beeler PE, Seger DL, et al. A cross-sectional observational study of high override rates of drug allergy alerts in inpatient and outpatient settings, and opportunities for improvement. BMJ Qual Saf. 2017;26(3):217-225.
Wong A, Amato MG, Seger DL, et al. Prospective evaluation of medication-related clinical decision support over-rides in the intensive care unit. BMJ Qual Saf. 2018;27(9):718-724.
Matricardi PM, Dramburg S, Alvarez-Perea A, et al. The role of mobile health technologies in allergy care: an EAACI position paper. Allergy. 2019. [Epub ahead of print]
Brozek JL, Akl EA, Alonso-Coello P, et al. Grading quality of evidence and strength of recommendations in clinical practice guidelines. Part 1 of 3. An overview of the GRADE approach and grading quality of evidence about interventions. Allergy. 2009;64(5):669-677.
Brozek JL, Akl EA, Compalati E, et al. Grading quality of evidence and strength of recommendations in clinical practice guidelines part 3 of 3. The GRADE approach to developing recommendations. Allergy. 2011;66(5):588-595.
Brozek JL, Akl EA, Jaeschke R, et al. Grading quality of evidence and strength of recommendations in clinical practice guidelines: Part 2 of 3. The GRADE approach to grading quality of evidence about diagnostic tests and strategies. Allergy. 2009;64(8):1109-1116.
Eigenmann PA, Akdis C, Bousquet J, et al. Highlights and recent developments in food and drug allergy, and anaphylaxis in EAACI Journals (2017). Pediatr Allergy Immunol. 2018;29(8):801-807.
Pichler WJ. Immune pathomechanism and classification of drug hypersensitivity. Allergy. 2019;74(8):1457-1471.
Muraro A, Lemanske RF Jr, Castells M, et al. Precision medicine in allergic disease-food allergy, drug allergy, and anaphylaxis-PRACTALL document of the European academy of allergy and clinical immunology and the American academy of allergy. Asthma and immunology. Allergy. 2017;72(7):1006-1021.
Cavkaytar O, du Toit G, Caimmi D. Characteristics of NSAID-induced hypersensitivity reactions in childhood. Pediatr Allergy Immunol. 2019;30(1):25-35.
Arikoglu T, Aslan G, Yildirim DD, Batmaz SB, Kuyucu S. Discrepancies in the diagnosis and classification of nonsteroidal anti-inflammatory drug hypersensitivity reactions in children. Allergol Int. 2017;66(3):418-424.
Chiriac AM, Wang Y, Schrijvers R, et al. Designing predictive models for beta-lactam allergy using the drug allergy and hypersensitivity database. J Allergy Clin Immunol Pract. 2018;6(1):139-148.e2.
Chiriac AM, Banerji A, Gruchalla RS, et al. Controversies in drug allergy: drug allergy pathways. J Allergy Clin Immunol Pract. 2019;7(1): 46-60.e4.
Hjortlund J, Mortz CG, Skov PS, Bindslev-Jensen C. Diagnosis of penicillin allergy revisited: the value of case history, skin testing, specific IgE and prolonged challenge. Allergy. 2013;68(8):1057-1064.
Landry Q, Zhang S, Ferrando L, Bourrain JL, Demoly P, Chiriac AM. Multiple drug hypersensitivity syndrome in a large database. J Allergy Clin Immunol Pract. 2019. [Epub ahead of print]
Blumenthal KG, Li Y, Acker WW, et al. Multiple drug intolerance syndrome and multiple drug allergy syndrome: Epidemiology and associations with anxiety and depression. Allergy. 2018;73(10):2012-2023.
Torres MJ, Romano A, Celik G, et al. Approach to the diagnosis of drug hypersensitivity reactions: similarities and differences between Europe and North America. Clin Transl Allergy. 2017;7:7.
Torres MJ, Celik GE, Whitaker P, et al. A EAACI drug allergy interest group survey on how European allergy specialists deal with beta-lactam allergy. Allergy. 2019;74(6):1052-1062.
Brockow K, Garvey LH, Aberer W, et al. Skin test concentrations for systemically administered drugs - an ENDA/EAACI drug allergy interest group position paper. Allergy. 2013;68(6):702-712.
Broz P, Harr T, Hecking C, et al. Nonirritant intradermal skin test concentrations of ciprofloxacin, clarithromycin, and rifampicin. Allergy. 2012;67(5):647-652.
Van Gasse AL, Sabato V, Uyttebroek AP, et al. Immediate moxifloxacin hypersensitivity: Is there more than currently meets the eye? Allergy. 2017;72(12):2039-2043.
Macy E, Shu YH. The effect of penicillin allergy testing on future health care utilization: a matched cohort study. J Allergy Clin Immunol Pract. 2017;5(3):705-710.
Brockow K, Romano A, Aberer W, et al. Skin testing in patients with hypersensitivity reactions to iodinated contrast media - a European multicenter study. Allergy. 2009;64(2):234-241.
Schrijvers R, Breynaert C, Ahmedali Y, Bourrain JL, Demoly P, Chiriac AM. Skin testing for suspected iodinated contrast media hypersensitivity. J Allergy Clin Immunol Pract. 2018;6(4):1246-1254.
Pagani M, Bavbek S, Dursun AB, et al. Role of skin tests in the diagnosis of immediate hypersensitivity reactions to taxanes: results of a multicenter study. J Allergy Clin Immunol Pract. 2019;7(3):990-997.
Faitelson Y, Boaz M, Dalal I. Asthma, family history of drug allergy, and age predict amoxicillin allergy in children. J Allergy Clin Immunol Pract. 2018;6(4):1363-1367.
Diaferio L, Chiriac AM, Leoni MC, et al. Skin tests are important in children with β-lactam hypersensitivity, but may be reduced in number. Pediatr Allergy Immunol. 2019;30(4):462-468.
Atanaskovic-Markovic M, Gomes E, Cernadas JR, et al. Diagnosis and management of drug-induced anaphylaxis in children: an EAACI position paper. Pediatr Allergy Immunol. 2019;30(3):269-276.
Trubiano JA, Douglas AP, Goh M, Slavin MA, Phillips EJ. The safety of antibiotic skin testing in severe T-cell-mediated hypersensitivity of immunocompetent and immunocompromised hosts. J Allergy Clin Immunol Pract. 2019;7(4):1341-1343.e1.
Phillips EJ, Bigliardi P, Bircher AJ, et al. Controversies in drug allergy: testing for delayed reactions. J Allergy Clin Immunol. 2019;143(1):66-73.
Galvan-Blasco P, Guilarte M, Cardona V, et al. Delayed drug hypersensitivity to bortezomib: desensitization and tolerance to its analogue carfilzomib. Allergy. 2019;74(7):1384-1386.
Fernandez TD, Mayorga C, Salas M, et al. Evolution of diagnostic approaches in betalactam hypersensitivity. Expert Rev Clin Pharmacol. 2017;10(6):671-683.
Aberer W, Bircher A, Romano A, et al. Drug provocation testing in the diagnosis of drug hypersensitivity reactions: general considerations. Allergy. 2003;58(9):854-863.
Demoly P, Romano A, Botelho C, et al. Determining the negative predictive value of provocation tests with beta-lactams. Allergy. 2010;65(3):327-332.
Chiriac A-M, Rerkpattanapipat T, Bousquet P-J, Molinari N, Demoly P. Optimal step doses for drug provocation tests to prove beta-lactam hypersensitivity. Allergy. 2017;72(4):552-561.
Fransson S, Mosbech H, Kappel M, et al. The importance of prolonged provocation in drug allergy - results from a Danish allergy clinic. J Allergy Clin Immunol Pract. 2017;5(5):1394-1401.
Labrosse R, Paradis L, Lacombe-Barrios J, et al. Efficacy and safety of 5-day challenge for the evaluation of nonsevere amoxicillin allergy in children. J Allergy Clin Immunol Pract. 2018;6(5):1673-1680.
Cortellini G, Romano A, Santucci A, et al. Clinical approach on challenge and desensitization procedures with aspirin in patients with ischemic heart disease and nonsteroidal anti-inflammatory drug hypersensitivity. Allergy. 2017;72(3):498-506.
Losappio LM, Cappai A, Arcolaci A, et al. Anxiety and depression effects during drug provocation test. J Allergy Clin Immunol Pract. 2018;6(5):1637-1641.
Iammatteo M, Alvarez Arango S, Ferastraoaru D, et al. Safety and outcomes of oral graded challenges to amoxicillin without prior skin testing. J Allergy Clin Immunol Pract. 2019;7(1):236-243.
Ebo DG, Leysen J, Mayorga C, Rozieres A, Knol EF, Terreehorst I. The in vitro diagnosis of drug allergy: status and perspectives. Allergy. 2011;66(10):1275-1286.
Mayorga C, Celik G, Rouzaire P, et al. In vitro tests for drug hypersensitivity reactions: an ENDA/EAACI drug allergy interest group position paper. Allergy. 2016;71(8):1103-1134.
Mayorga C, Ebo DG, Lang DM, et al. Controversies in drug allergy: in vitro testing. J Allergy Clin Immunol. 2019;143(1):56-65.
Dona I, Torres MJ, Montanez MI, Fernandez TD. In vitro diagnostic testing for antibiotic allergy. Allergy Asthma Immunol Res. 2017;9(4):288-298.
Mayorga C, Dona I, Perez-Inestrosa E, Fernandez TD, Torres MJ. The value of in vitro tests to diminishdrug challenges. Int J Mol Sci. 2017;18(6):1222.
Antunez C, Fernandez T, Blanca-Lopez N, et al. IgE antibodies to betalactams: relationship between the triggering hapten and the specificity of the immune response. Allergy. 2006;61(8):940-946.
Blanca M, Mayorga C, Torres MJ, et al. Clinical evaluation of pharmacia CAP system RAST FEIA amoxicilloyl and benzylpenicilloyl in patients with penicillin allergy. Allergy. 2001;56(9):862-870.
Fontaine C, Mayorga C, Bousquet PJ, et al. Relevance of the determination of serum-specific IgE antibodies in the diagnosis of immediate beta-lactam allergy. Allergy. 2007;62(1):47-52.
Aranda A, Mayorga C, Ariza A, et al. In vitro evaluation of IgE-mediated hypersensitivity reactions to quinolones. Allergy. 2011;66(2):247-254.
Ben Said B, Berard F, Bienvenu J, Nicolas JF, Rozieres A. Usefulness of basophil activation tests for the diagnosis of IgE-mediated allergy to quinolones. Allergy. 2010;65(4):535-536.
Chirumbolo S. Basophil activation test (BAT) in the diagnosis of immediate hypersensitivity reactions to radiocontrast media. Allergy. 2013;68(12):1627-1628.
Hoffmann HJ, Santos AF, Mayorga C, et al. The clinical utility of basophil activation testing in diagnosis and monitoring of allergic disease. Allergy. 2015;70(11):1393-1405.
Gamboa PM, Sanz ML, Caballero MR, et al. Use of CD63 expression as a marker of in vitro basophil activation and leukotriene determination in metamizol allergic patients. Allergy. 2003;58(4):312-317.
Garcia-Ortega P, Marin A. Usefulness of the basophil activation test (BAT) in the diagnosis of life-threatening drug anaphylaxis. Allergy.2010;65(9):1204.
Kvedariene V, Kamey S, Ryckwaert Y, et al. Diagnosis of neuromuscular blocking agent hypersensitivity reactions using cytofluorimetric analysis of basophils. Allergy. 2006;61(3):311-315.
Salas M, Fernandez-Santamaria R, Mayorga C, et al. Use of the basophil activation test may reduce the need for drug provocation in amoxicillin-clavulanic allergy. J Allergy Clin Immunol Pract. 2018;6(3):1010-1018.e2.
Fernandez TD, Torres MJ, Blanca-Lopez N, et al. Negativization rates of IgE radioimmunoassay and basophil activation test in immediate reactions to penicillins. Allergy. 2009;64(2):242-248.
Laguna JJ, Bogas G, Salas M, et al. The basophil activation test can be of value for diagnosing immediate allergic reactions to omeprazole. J Allergy Clin Immunol Pract. 2018;6(5):1628-1636 e.2.
Li J, Best OG, Rose MA, Green SL, Fulton RB, Fernando SL. Integrating basophil activation tests into evaluation of perioperative anaphylaxis to neuromuscular blocking agents. Br J Anaesth. 2019;123(1):e135-e143.
Dewachter P, Chollet-Martin S, Mouton-Faivre C, de Chaisemartin L, Nicaise-Roland P. Comparison of basophil activation test and skin testing performances in NMBA allergy. J Allergy Clin Immunol Pract. 2018;6(5):1681-1689.
Ariza A, Garcia-Martin E, Salas M, et al. Pyrazolones metabolites are relevant for identifying selective anaphylaxis to metamizole. Sci Rep. 2016;6:23845.
Barbero N, Fernandez-Santamaria R, Mayorga C, et al. Identification of an antigenic determinant of clavulanic acid responsible for IgE-mediated reactions. Allergy. 2019;74(8):1490-1501.
Molina N, Martin-Serrano A, Fernandez TD, et al. Dendrimeric antigens for drug allergy diagnosis: a new approach for basophil activation tests. Molecules. 2018;23(5):997.
Giavina-Bianchi P, Galvao VR, Picard M, Caiado J, Castells MC. Basophil activation test is a relevant biomarker of the outcome of rapid desensitization in platinum compounds-allergy. J Allergy Clin Immunol Pract. 2017;5(3):728-736.
Montanez MI, Mayorga C, Bogas G, et al. Epidemiology, mechanisms, and diagnosis of drug-induced anaphylaxis. Front Immunol. 2017;8:614.
Baretto RL, Beck S, Heslegrave J, et al. Validation of international consensus equation for acute serum total tryptase in mast cell activation: a perioperative perspective. Allergy. 2017;72(12):2031-2034.
Beeler A, Zaccaria L, Kawabata T, Gerber BO, Pichler WJ. CD69 upregulation on T cells as an in vitro marker for delayed-type drug hypersensitivity. Allergy. 2008;63(2):181-188.
Kano Y, Hirahara K, Mitsuyama Y, Takahashi R, Shiohara T. Utility of the lymphocyte transformation test in the diagnosis of drug sensitivity: dependence on its timing and the type of drug eruption. Allergy. 2007;62(12):1439-1444.
Pichler WJ, Tilch J. The lymphocyte transformation test in the diagnosis of drug hypersensitivity. Allergy. 2004;59(8):809-820.
Haw WY, Polak ME, McGuire C, Erlewyn-Lajeunesse M, Ardern-Jones MR. In vitro rapid diagnostic tests for severe drug hypersensitivity reactions in children. Ann Allergy Asthma Immunol. 2016;117(1):61-66.
Lochmatter P, Beeler A, Kawabata TT, Gerber BO, Pichler WJ. Drug-specific in vitro release of IL-2, IL-5, IL-13 and IFN-gamma in patients with delayed-type drug hypersensitivity. Allergy. 2009;64(9):1269-1278.
Martin M, Wurpts G, Ott H, et al. In vitro detection and characterization of drug hypersensitivity using flow cytometry. Allergy. 2010;65(1):32-39.
Zawodniak A, Lochmatter P, Yerly D, et al. In vitro detection of cytotoxic T and NK cells in peripheral blood of patients with various drug-induced skin diseases. Allergy. 2010;65(3):376-384.
Trubiano JA, Strautins K, Redwood AJ, et al. The combined utility of ex vivo IFN-gamma release enzyme-linked immunospot assay and in vivo skin testing in patients with antibiotic-associated severe cutaneous adverse reactions. J Allergy Clin Immunol Pract 2018;6(4):1287-1296 e.1.
Kato K, Kawase A, Azukizawa H, et al. Novel interferon-gamma enzyme-linked immunoSpot assay using activated cells for identifying hypersensitivity-inducing drug culprits. J Dermatol Sci. 2017;86(3):222-229.
McNeil BD, Pundir P, Meeker S, et al. Identification of a mast-cell-specific receptor crucial for pseudo-allergic drug reactions. Nature. 2015;519(7542):237-241.
Eguiluz-Gracia I, Tay TR, Hew M, et al. Recent developments and highlights in biomarkers in allergic diseases and asthma. Allergy. 2018;73(12):2290-2305.
Mastalerz L, Tyrak KE, Ignacak M, et al. Prostaglandin E2 decrease in induced sputum of hypersensitive asthmatics during oral challenge with aspirin. Allergy. 2019;74(5):922-932.
Zellweger F, Eggel A. IgE-associated allergic disorders: recent advances in etiology, diagnosis, and treatment. Allergy. 2016;71(12):1652-1661.
Ariza A, Mayorga C, Fernandez TD, et al. Hypersensitivity reactions to beta-lactams: relevance of hapten-protein conjugates. J Investig Allergol Clin Immunol. 2015;25(1):12-25.
Ariza A, Mayorga C, Salas M, et al. The influence of the carrier molecule on amoxicillin recognition by specific IgE in patients with immediate hypersensitivity reactions to betalactams. Sci Rep. 2016;6:35113.
Azoury ME, Fili L, Bechara R, et al. Identification of T-cell epitopes from benzylpenicillin conjugated to human serum albumin and implication in penicillin allergy. Allergy. 2018;73(8):1662-1672.
Bechara R, Maillere B, Joseph D, Weaver RJ, Pallardy M. Identification and characterization of a naive CD8+ T cell repertoire for benzylpenicillin. Clin Exp Allergy. 2019;49(5):636-643.
Sanchez-Gomez FJ, Gonzalez-Morena JM, Vida Y, et al. Amoxicillin haptenates intracellular proteins that can be transported in exosomes to target cells. Allergy. 2017;72(3):385-396.
Amali MO, Sullivan A, Jenkins RE, et al. Detection of drug-responsive B lymphocytes and antidrug IgG in patients with beta-lactam hypersensitivity. Allergy. 2017;72(6):896-907.
Perkins JR, Acosta-Herrera M, Plaza-Seron MC, et al. Polymorphisms in CEP68 gene associated with risk of immediate selective reactions to non-steroidal anti-inflammatory drugs. Pharmacogenomics J. 2019;19(2):191-199.
Ferreira Vasconcelos LM, Rodrigues RO, Albuquerque AA, et al. Polymorphism of IL10, IL4, CTLA4, and DAO genes in cross-reactive nonsteroidal anti-inflammatory drug hypersensitivity. J Clin Pharmacol. 2018;58(1):107-113.
Fernandez TD, Mayorga C, Torres MJ, et al. Cytokine and chemokine expression in the skin from patients with maculopapular exanthema to drugs. Allergy. 2008;63(6):712-719.
Chaves P, Torres MJ, Aranda A, et al. Natural killer-dendritic cell interaction in lymphocyte responses in hypersensitivity reactions to betalactams. Allergy. 2010;65(12):1600-1608.
Fernandez-Santamaria R, Palomares F, Salas M, et al. Expression of the Tim3-galectin-9 axis is altered in drug-induced maculopapular exanthema. Allergy. 2019;74(9):1769-1779.
Sullivan A, Wang E, Farrell J, et al. Beta-lactam hypersensitivity involves expansion of circulating and skin-resident TH22 cells. J Allergy Clin Immunol. 2018;141(1):235-249 e.8.
Monroy-Arreola A, Duran-Figueroa NV, Mendez-Flores S, et al. Up-regulation of T-cell activation microRNAs in drug-specific CD4(+) T-cells from hypersensitive patients. Chem Res Toxicol. 2018;31(6):454-461.
Wu Y, Farrell J, Pirmohamed M, Park BK, Naisbitt DJ. Generation and characterization of antigen-specific CD4+, CD8+, and CD4+CD8+ T-cell clones from patients with carbamazepine hypersensitivity. J Allergy Clin Immunol. 2007;119(4):973-981.
Tsai YG, Liou JH, Hung SI, et al. Increased type 2 innate lymphoid cells in patients with drug reaction with eosinophilia and systemic symptoms syndrome. J Invest Dermatol. 2019; 139(8):1722-1731.
Takahashi R, Kano Y, Yamazaki Y, Kimishima M, Mizukawa Y, Shiohara T. Defective regulatory T cells in patients with severe drug eruptions: timing of the dysfunction is associated with the pathological phenotype and outcome. J Immunol. 2009;182(12):8071-8079.
Ushigome Y, Mizukawa Y, Kimishima M, et al. Monocytes are involved in the balance between regulatory T cells and Th17 cells in severe drug eruptions. Clin Exp Allergy. 2018;48(11):1453-1463.
Ogese MO, Faulkner L, Jenkins RE, et al. Characterization of drug-specific signaling between primary human hepatocytes and immune cells. Toxicol Sci. 2017;158(1):76-89.
Meng X, Yerly D, Naisbitt DJ. Mechanisms leading to T-cell activation in drug hypersensitivity. Curr Opin Allergy Clin Immunol. 2018;18(4):317-324.
Sullivan A, Watkinson J, Waddington J, Park BK, Naisbitt DJ. Implications of HLA-allele associations for the study of type IV drug hypersensitivity reactions. Expert Opin Drug Metab Toxicol. 2018;14(3):261-274.
Negrini S, Becquemont L. Pharmacogenetics of hypersensitivity drug reactions. Therapie. 2017;72(2):231-243.
Yerly D, Pompeu YA, Schutte RJ, et al. Structural elements recognized by abacavir-induced T cells. Int J Mol Sci. 2017;18(7):1464.
Pavlos R, McKinnon EJ, Ostrov DA, et al. Shared peptide binding of HLA Class I and II alleles associate with cutaneous nevirapine hypersensitivity and identify novel risk alleles. Sci Rep. 2017;7(1):8653.
Toksoy A, Sennefelder H, Adam C, et al. Potent NLRP3 inflammasome activation by the HIV reverse transcriptase inhibitor abacavir. J Biol Chem. 2017;292(7):2805-2814.
Gibson A, Faulkner L, Lichtenfels M, et al. The effect of inhibitory signals on the priming of drug hapten-specific T cells that express distinct vbeta receptors. J Immunol. 2017;199(4):1223-1237.
Brockow K, Aberer W, Atanaskovic-Markovic M, et al. Drug allergy passport and other documentation for patients with drug hypersensitivity - An ENDA/EAACI Drug Allergy Interest Group Position Paper. Allergy. 2016;71(11):1533-1539.
Lee FY, Chan HK, Wong HS. Effectiveness of drug allergy card to prevent repeated prescribing of allergenic medications in a Malaysian public hospital. Pharmacoepidemiol Drug Saf. 2019;28(5):760-761.
Sacco KA, Bates A, Brigham TJ, Imam JS, Burton MC. Clinical outcomes following inpatient penicillin allergy testing: a systematic review and meta-analysis. Allergy. 2017;72(9):1288-1296.
Tanno LK, Torres MJ, Castells M, Demoly P, Joint AA. What can we learn in drug allergy management from world health organization's international classifications? Allergy. 2018;73(5):987-992.
Baeck M, Chemelle JA, Goossens A, Nicolas JF, Terreux R. Corticosteroid cross-reactivity: clinical and molecular modelling tools. Allergy. 2011;66(10):1367-1374.
De Luca F, Losappio LM, Mirone C, et al. Tolerated drugs in subjects with severe cutaneous adverse reactions (SCARs) induced by anticonvulsants and review of the literature. Clin Mol Allergy. 2017;15:16.
Al-Ahmad M, Rodriguez-Bouza T. Drug allergy evaluation for betalactam hypersensitivity: cross-reactivity with cephalosporines, carbapenems and negative predictive value. Asian Pac J Allergy Immunol. 2018;36(1):27-31.
Han SH, Hur MS, Youn HJ, et al. Drug reaction with eosinophilia and systemic symptom syndrome induced by lamotrigine. Ann Dermatol. 2017;29(2):206-209.
Allouchery M, Logerot S, Cottin J, et al. Antituberculosis drug-associated DRESS: a case series. J Allergy Clin Immunol Pract. 2018;6(4):1373-1380.
Liang J, Qu H, Wang X, et al. Drug reaction with eosinophilia and systemic symptoms associated with reactivation of epstein-barr virus and/or cytomegalovirus leading to hemophagocytic syndrome in one of two patients. Ann Dermatol. 2018;30(1):71-74.
Pornwattanakrilert W, Suprasert P. Comparison of hypersensitivity reactions to carboplatin retreatment in gynecologic cancer patients between one and two hour infusions: a randomized trial study. Asian Pac J Cancer Prev. 2017;18(2):425-430.
Castells M. Diagnosis and management of anaphylaxis in precision medicine. J Allergy Clin Immunol. 2017;140(2):321-333.
Chung SJ, Kang SY, Kang RY, et al. A new non-dilution rapid desensitization protocol successfully applied to all-grade platinum hypersensitivity. Cancer Chemother Pharmacol. 2018;82(5):777-785.
Madrigal-Burgaleta R, Bernal-Rubio L, Berges-Gimeno MP, Carpio-Escalona LV, Gehlhaar P, Alvarez-Cuesta E. A large single-hospital experience using drug provocation testing and rapid drug desensitization in hypersensitivity to antineoplastic and biological agents. J Allergy Clin Immunol Pract. 2019;7(2):618-632.
Cernadas JR, Brockow K, Romano A, et al. General considerations on rapid desensitization for drug hypersensitivity - a consensus statement. Allergy. 2010;65(11):1357-1366.
de Las Vecillas Sanchez L, L, Alenazy L, Garcia-Neuer M, Castells M. Drug hypersensitivity and desensitizations: mechanisms and new approaches. Int J Mol Sci. 2017;18(6):1316.
Perez-Rodriguez E, Martinez-Tadeo JA, Perez-Rodriguez N, et al. Outcome of 490 desensitizations to chemotherapy drugs with a rapid one-solution Protocol. J Allergy Clin Immunol Pract. 2018;6(5): 1621-1627.e6.
Lopez-Gonzalez P, Madrigal-Burgaleta R, Carpio-Escalona LV, et al. Assessment of antihistamines and corticosteroids as premedication in rapid drug desensitization to paclitaxel: outcomes in 155 procedures. J Allergy Clin Immunol Pract. 2018;6(4):1356-1362.
Gan H, Wang L, Fu W, Zhang J, Yu M, Liu G. Rapid subcutaneous desensitization for the management of delayed hypersensitivity reactions to omalizumab: a case report. J Clin Pharm Ther. 2019;44(3):486-488.
Prieto-Garcia A, Noguerado B, Rojas P, Torrado I, Rodriguez-Fernandez A, Tornero P. Unexpected anaphylaxis after completing a desensitization protocol to oxaliplatin: successful adjuvant use of omalizumab. J Investig Allergol Clin Immunol. 2019;29(1):53-55.
Al-Ahmad M, Rodriguez-Bouza T, Nurkic M. Establishing a safe administration of ASA in cardiovascular patients with nonsteroidal anti-inflammatory drug hypersensitivity with skin and/or respiratory involvement. Int Arch Allergy Immunol. 2018;175(4):237-245.
Sanchez-Borges M, Aberer W, Brockow K, et al. Controversies in drug allergy: radiographic contrast media. J Allergy Clin Immunol Pract. 2019;7(1):61-65.
Waljee AK, Rogers MA, Lin P, et al. Short term use of oral corticosteroids and related harms among adults in the United States: population based cohort study. BMJ. 2017;357:j1415.
Ban GY, Jeong YJ, Lee SH, et al. Efficacy and tolerability of desensitization in the treatment of delayed drug hypersensitivities to anti-tuberculosis medications. Respir Med. 2019;147:44-50.
Siripassorn K, Ruxrungtham K, Manosuthi W. Successful drug desensitization in patients with delayed-type allergic reactions to anti-tuberculosis drugs. Int J Infect Dis. 2018;68:61-68.
Dilley MA, Lee JP, Broyles AD. Methotrexate hypersensitivity reactions in pediatrics: evaluation and management. Pediatr Blood Cancer. 2017;64(5):e26306.
Shah SR, Millan T, Alamzaib SM, Luu SW. Desensitization therapy using 'Mariana Castells' protocol in a patient with multiple autoimmune disorders- does it work? J Community Hosp Intern Med Perspect. 2019;9(1):53-54.
Rial Prado MJ, Rico Diaz MA, Cosgaya Ceballos A, Cuesta HJ. A new rush schedule for cotrimoxazole desensitization: a report of 2 cases. J Investig Allergol Clin Immunol. 2018;28(4):267-269.
Heath JL, Heath RD, Tamboli C, et al. Mesalamine desensitization in a patient with treatment refractory ulcerative colitis and aspirin and nonsteroidal anti-inflammatory drug hypersensitivity. Ann Allergy Asthma Immunol. 2017;118(4):518-520.
Kidon M, Blanca-Lopez N, Gomes E, et al. EAACI/ENDA position paper: diagnosis and management of hypersensitivity reactions to non-steroidal anti-inflammatory drugs (NSAIDs) in children and adolescents. Pediatr Allergy Immunol. 2018;29(5):469-480.
Rosa JS, Vuong VB, Haskin O, Liu AY. A novel outpatient desensitization protocol for recombinant human erythropoietin allergy in a pediatric patient. Allergy Asthma Clin Immunol 2018;14:8.
Bahloul N, Ben Mahmoud L, Ghozzi H, et al. Hypersensitivity to levothyroxine: a case report of a successful oral desensitization. Therapie. 2018;73(4):349-350.
Breiteneder H, Diamant Z, Eiwegger T, et al. Future research trends in understanding the mechanisms underlying allergic diseases for improved patient care. Allergy. 2019; 1-19.
Torres MJ, Fernandez TD. Highlights of the 8th drug hypersensitivity meeting: amsterdam, April 19-21, 2018. Allergy. 2018;73(10):1941-1943.